WO2008077618A1 - Verwendung von xanthohumol bzw. isoxanthohumol als wirkstoff zur vorbeugung und/oder bekämpfung von lebererkrankungen - Google Patents

Verwendung von xanthohumol bzw. isoxanthohumol als wirkstoff zur vorbeugung und/oder bekämpfung von lebererkrankungen Download PDF

Info

Publication number
WO2008077618A1
WO2008077618A1 PCT/EP2007/011358 EP2007011358W WO2008077618A1 WO 2008077618 A1 WO2008077618 A1 WO 2008077618A1 EP 2007011358 W EP2007011358 W EP 2007011358W WO 2008077618 A1 WO2008077618 A1 WO 2008077618A1
Authority
WO
WIPO (PCT)
Prior art keywords
xanthohumol
body weight
use according
isoxanthohumol
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/011358
Other languages
German (de)
English (en)
French (fr)
Inventor
Claus Hellerbrand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JOH BARTH and SOHN GmbH and Co KG
Original Assignee
JOH BARTH and SOHN GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JOH BARTH and SOHN GmbH and Co KG filed Critical JOH BARTH and SOHN GmbH and Co KG
Priority to CA2672155A priority Critical patent/CA2672155C/en
Priority to EP20070857069 priority patent/EP2120906B1/de
Priority to JP2009541912A priority patent/JP5513126B2/ja
Priority to US12/520,756 priority patent/US20100029757A1/en
Publication of WO2008077618A1 publication Critical patent/WO2008077618A1/de
Anticipated expiration legal-status Critical
Priority to US14/074,332 priority patent/US20140066519A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3486—Humulus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • xanthohumol or isoxanthohumol as an active ingredient for the prevention and / or control of liver diseases
  • the present invention relates to the use of xanthohumol or isoxanthohumol as an active ingredient for the prevention and / or control of liver diseases.
  • Xanthohumol is a prenylflavenoid found in hops. Various studies show biological effects of xanthohumol.
  • EP 1 543 834 A1 describes the anti-carcinogenic effect of xanthohumol.
  • the present invention has set itself the task of finding other health-promoting applications of xanthohumol and isoxanthohumol.
  • xanthohumol as an active ingredient for the preparation of a preparation for the prevention and / or control of liver diseases.
  • isoxanthohumol as an active ingredient for the preparation of a preparation for the prevention and / or treatment of liver diseases.
  • the claimed use has the advantage that liver diseases using a natural active substance can be effectively prevented or combated both preventively and by treatment.
  • Xanthohumol or Isoxanthohumol have no side effects. This makes it possible to prophylactically prevent over a long time chronic liver disease, especially chronic liver disease by regular ingestion.
  • xanthohumol or isoxanthohumol for the prevention or acute treatment of liver cirrhosis or liver fibrosis. It has surprisingly been found in studies that xanthohumol inhibits metabolic mechanisms of particular importance for obesity (overweight) and diabetes mediated liver damage. Obesity and diabetes are responsible for a large proportion of liver cirrhosis. The tendency is rising. Overall, chronic Liver disease is now a major economic problem dar. Through continuous intake of xanthohumol or isoxanthohumol effective prophylactic protection without side effects for the entire population can be established.
  • xanthohumol or isoxanthohumol also have antiviral properties and show very good activity against hepatitis, in particular against hepatitis B and hepatitis C.
  • Hepatitis B or hepatitis C is the leading cause of chronic liver disease.
  • Epidemiological studies in Germany have shown that about 2% of the population suffer from chronic hepatitis B or hepatitis C. It is therefore also a problem of central social importance. Due to the prophylactic uptake of xanthohumol or isoxanthohumol on the one hand, the proportion of hepatitis diseases, d. H. On the other hand, the course of an existing hepatitis disease can be favorably influenced.
  • xanthohumol or isoxanthohumol also has anti-carcinogenic effects.
  • liver cancer or hepatocellular carcinoma (HCC) there is currently no proven therapy in addition to the surgical method, which would improve the survival of the patients.
  • HCC hepatocellular carcinoma
  • xanthohumol or isoxanthohumol can be used prophylactically in people with a high risk profile (genetic risk, obese, diabetics).
  • xanthohumol or isoxanthohumol as an active ingredient of a pharmaceutical composition with a pharmaceutically acceptable carrier such.
  • a pharmaceutically acceptable carrier such as mannitol, sucrose, lactose, glucose, fructose, maltose, etc. are supplied.
  • Xanthohumol or isoxanthohumol is particularly suitable for being added to a foodstuff as active ingredient or to be added to a drink.
  • xanthohumol or isoxanthohumol as the active ingredient takes place, in particular, specifically in the activity of free oxygen radicals in the Reduce or eliminate the liver.
  • free oxygen radicals resulting in the development of liver inflammation, Leberf ⁇ brose or Liver cirrhosis as well as contributing to liver cancer.
  • the formation of free oxygen radicals is inhibited by the xanthohumol or isoxanthohumol or impaired their activity. This has the advantage that all three aforementioned damage mechanisms of the liver can be influenced equally effectively by xanthohumol or isoxanthohumol.
  • NF-kappa B factor i. H. in particular to reduce or eliminate its activity.
  • NF-Kappa-B is an intermediary of signals in the cell and involved in the modulation of numerous cell functions. It has been found that the NF-kappa B factor plays a very special role in the aforementioned three damage mechanisms of the liver. NF-Kappa-B also plays an important role in the genesis and progression of NASH.
  • the xanthohumol or isoxanthohumol can be used surprisingly in comparatively high dosages. Because it has been found that even at higher dosages no cell damaging effect of xanthohumol or isoxanthohumol occurs, so that a selective effectiveness is given. It has been found that with increasing dosage of xanthohumol or isoxanthohumol, for example, beginning with a lower limit of 5 ⁇ M, a continuous increase of the positive effect can be detected, in particular up to a maximum limit of 100 ⁇ M.
  • the active ingredient, d. H. the xanthohumol or isoxanthohumol or a metabolite thereof or a precursor thereof in a dosage form apply, so that in the liver drug concentrations> 5 uM, in particular> 10 uM, in particular> 20 uM, in particular> 30 ⁇ M, in particular> 40 uM, in particular set> 50 uM.
  • the active ingredient is to be used in a dosage form such that an active ingredient concentration of not more than 100 ⁇ M is established in the liver.
  • the respective active ingredient is to be used in a dosage form, so that in the liver drug concentrations in the following Adjust ranges, 1 to 100 uM, preferably 1-25 uM, preferably 1-10 uM or 5-100 uM, preferably 10-50 uM, preferably 10-25 uM.
  • the relevant areas can be selected. In particular, in the treatment of fibrosis already comparatively low dosages are sufficient, whereas in the treatment of liver cancer increased dosages are expedient.
  • xanthohumol or isoxanthohumol is administered, for example, to the diet or as a tablet, it can therefore lead to comparatively high xanthohumol or isoxanthohumol levels due to uptake via the intestine, which however rapidly dilute after passage through the liver, i. in no other organ even an approximately as high xanthohumol level is reached anymore.
  • xanthohumol or isoxanthohumol instead of xanthohumol or isoxanthohumol, according to the present invention, it is also possible to use a metabolite thereof, in particular a
  • Metabolite which arises in the liver due to the P 450 enzyme complex.
  • xanthohumol glucuronides sulfates, methylated forms of xanthohumol or naringenins, in particular the
  • Naringenin especially 8-prenyl-naringenin, is the final metabolite of xanthohumol.
  • xanthohumol or isoxanthohumol instead of xanthohumol or isoxanthohumol, a precursor thereof can be used which regenerates under chemical and / or physiological conditions to xanthohumol. All uses of xanthohumol and isoxanthohumol for the treatment of liver diseases described in this application therefore also apply to the above-described metabolites or precursors.
  • a composition may be used as an active ingredient in which xanthohumol and / or isoxanthohumol is not present in pure form but as a hops extraction product. It has been found that in addition to the xanthohumol or isoxanthohumol present carrier components, which are produced by the production, the absorption of the active substance in the organism and thus the effectiveness can even support.
  • the dose for administration of the active substance based on the respective (pure) proportion of active substance is greater than 0.01 mg / kg body weight / day, preferably greater than 0.1 mg / kg body weight / day, preferably greater than 1 mg / kg body weight / day, preferably greater than 10 mg / kg body weight / day, preferably greater than 50 mg / kg body weight / day, preferably greater than 100 mg / kg body weight / day, the body weight being the body weight of a human ,
  • the dose for administration based on the respective (pure) proportion of active substance is less than 161 mg / kg body weight / day, preferably less than 50 mg / kg body weight / day, preferably less than 10 mg / kg body weight / day, preferably less than 1 mg / kg body weight / day, preferably less than 0.1 mg / kg body weight / day, wherein the body weight is the body weight of a human being.
  • the dose for administration based on the respective (pure) proportion of active substance is a range of 0.01 to 161 mg / kg body weight / day, preferably 0.05 to 120 mg / kg body weight / day, preferably 0.1 to 100 mg / kg body weight / day, preferably 0.5 to 80 mg / kg body weight / day, preferably 1 to 80 mg / kg body weight / day, preferably 5 to 80 mg / kg body weight / day, preferably 10 to 80 mg / kg Body weight / day, where body weight is the body weight of a human being.
  • xanthohumol as the active ingredient further ingredients, especially natural ingredients due to the extraction of xanthohumol from hops are present, this may even increase the effectiveness, since these ingredients cause an improved uptake of the drug in the organism.
  • the xanthohumol or isoxanthohumol can also be used in pure form.
  • the xanthohumol, isoxanthohumol, a metabolite thereof and / or a precursor thereof used in conjunction with at least one further active ingredient.
  • This active substance may preferably be an active substance which positively influences the compatibility and / or the uptake of the active substance to be administered in the body and / or its activity and / or its stability and / or its handling.
  • the xanthohumol or isoxanthohumol or a metabolite thereof or a precursor thereof can be used in conjunction with or on the basis of a salt, in particular an alkali metal or alkaline earth metal salt.
  • the agent to be administered can be used in particular as a liquid, porridge, emulsion, in the form of nanoparticles, as a powder or as a gel.
  • the administration can take place as an independent drug, but also as an additive to a liquid or solid food, depending on whether a therapy or a prophylaxis is desired.
  • the active ingredient may be prepared using pharmaceutically acceptable, nutrient-compatible or food-grade solvents, excipients or additives such.
  • dextrin especially cyclodextrin, maltodextrin, proteins, methyl cellulose, carbomethoxy cellulose or xanthan take place.
  • FIGS. 1-9 were carried out with xanthohumol in pure form (> 98%).
  • the following is an exemplary composition of a food supplemented with xanthohumol as an active ingredient.
  • Xanthohumol (pure substance in powder form) 500 mg per 200 ml
  • Dairy product creamy, eg yoghurt
  • the above composition for a food due to the ease of incorporation into a creamy food, allows optimum administration for the required amount of xanthohumol.
  • Figure 1 shows the therapeutic objectives of xanthohumol.
  • the presentation reflects the chain of mechanisms of action based on liver disease, for example due to alcohol, viruses, radiation, obesity and / or diabetes, up to liver cancer.
  • the use of a preparation with xanthohumol and / or isoxanthohumol advantageously affects all stages of the chain of action according to FIG. 1.
  • xanthohumol or isoxanthohumol can also be used successfully in the treatment of individual stations of the sites of action.
  • Figure 2 shows a schematic representation of the efficacy of xanthohumol and / or isoxanthohumol in a viral injury to the liver, in particular by hepatitis B and C. It has been found that the aforementioned
  • Active ingredients not only inhibit the virus multiplication in an advantageous manner, but also ensures a selective killing of the already affected by the virus endogenous liver cells, whereas healthy liver cells remain unaffected.
  • targeted therapy for reducing or eliminating liver cells infected with the virus is made possible.
  • FIG. 3 shows, by way of a diagram comparison, the selective effectiveness of the use of xanthohumol or isoxanthohumol in relation to hepatitis C-infected liver cells and hepatitis C-infected liver cells in comparison.
  • Figure 4 shows a graphic representation of the effectiveness of the use of xanthohumol with respect to apoptosis (programmed cell death) of liver cancer cells (HepG2) compared to healthy liver cells (primary human hepatocytes).
  • FIG. 5 shows a comparison of the growth of liver cancer cells (HepG2) over time as a function of the dosage of xanthohumol.
  • HepG2 liver cancer cells
  • Figures 6 and 7 illustrate the effect of adding xanthohumol with respect to preventing the transformation of autologous liver cells into hepatic stellate cells responsible for liver scarring in liver cirrhosis.
  • FIG. 8 shows an illustration of the effect of xanthohumol in increasing dosage on the already existing, activated hepatic stellate cells. From the illustration according to FIG. 6 it can be seen that with increasing dosage of xanthohumol an increased effect of killing (LDH) of activated, hepatic stellate cells sets in.
  • LDH killing
  • FIG. 9 shows the influence of the dosage of xanthohumol on the growth of the activated hepatic stellate cells.
  • FIG. 10 shows a comparison of the lifetime (proliferation) of liver cancer cells after the use of xanthohumol in pure form (> 98%) or in a form in which xanthohumol is present as a proportion of 60%.
  • the latter is the xanthohumol obtained from hop extract in a standard technical process which contains other natural components. The lower the bars, the more cells are inhibited in their growth.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PCT/EP2007/011358 2006-12-22 2007-12-21 Verwendung von xanthohumol bzw. isoxanthohumol als wirkstoff zur vorbeugung und/oder bekämpfung von lebererkrankungen Ceased WO2008077618A1 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2672155A CA2672155C (en) 2006-12-22 2007-12-21 Use of xanthohumol or isoxanthohumol as an active substance for the prevention and/or control of liver diseases
EP20070857069 EP2120906B1 (de) 2006-12-22 2007-12-21 Verwendung von xanthohumol als wirkstoff zur vorbeugung und/oder bekämpfung von lebererkrankungen
JP2009541912A JP5513126B2 (ja) 2006-12-22 2007-12-21 肝疾患を予防および／または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用
US12/520,756 US20100029757A1 (en) 2006-12-22 2007-12-21 Use of xanthohumol and/or isoxanthohumol as an agent for preventing and/or combating liver diseases
US14/074,332 US20140066519A1 (en) 2006-12-22 2013-11-07 Use of xanthohumol and/or isoxanthohumol as an agent for preventing and/or combating liver diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006062264A DE102006062264A1 (de) 2006-12-22 2006-12-22 Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen
DE102006062264.2 2006-12-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/520,756 A-371-Of-International US20100029757A1 (en) 2006-12-22 2007-12-21 Use of xanthohumol and/or isoxanthohumol as an agent for preventing and/or combating liver diseases
US14/074,332 Continuation-In-Part US20140066519A1 (en) 2006-12-22 2013-11-07 Use of xanthohumol and/or isoxanthohumol as an agent for preventing and/or combating liver diseases

Publications (1)

Publication Number Publication Date
WO2008077618A1 true WO2008077618A1 (de) 2008-07-03

Family

ID=39186950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/011358 Ceased WO2008077618A1 (de) 2006-12-22 2007-12-21 Verwendung von xanthohumol bzw. isoxanthohumol als wirkstoff zur vorbeugung und/oder bekämpfung von lebererkrankungen

Country Status (7)

Country Link
US (1) US20100029757A1 (enExample)
EP (1) EP2120906B1 (enExample)
JP (1) JP5513126B2 (enExample)
CA (1) CA2672155C (enExample)
DE (1) DE102006062264A1 (enExample)
RU (1) RU2454996C2 (enExample)
WO (1) WO2008077618A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064350A1 (en) * 2009-11-26 2011-06-03 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US9221751B2 (en) 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2017001020A1 (de) 2015-07-02 2017-01-05 Flaxan Gmbh & Co. Kg Substanz auf hopfenbasis sowie verwendung der substanz
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2861202B1 (en) 2012-06-18 2018-07-18 3M Innovative Properties Company Powder composition for air polishing the surface of hard dental tissue
BR112015001595A2 (pt) * 2012-07-26 2018-06-19 Ta-Xan Ag composição farmacêutica, uso de um extrato torrado, e, método para intensificar um ou mais efeito (s) terapêutico (s) de xantohumol e para a produção de uma composição farmacêutica
WO2014099490A2 (en) 2012-12-17 2014-06-26 3M Innovative Properties Company Device for dispensing a dental material with locking mechanism
EP2742898A1 (en) 2012-12-17 2014-06-18 3M Innovative Properties Company Powder jet device for dispensing a dental material
EP2742897A1 (en) 2012-12-17 2014-06-18 3M Innovative Properties Company Nozzle head, hand piece and powder jet device for applying a dental material
KR20190099481A (ko) * 2016-12-20 2019-08-27 산토리 홀딩스 가부시키가이샤 이소잔토휴몰을 함유하는 지질 대사 촉진용 조성물
DK3651804T5 (da) 2017-07-11 2023-10-09 Aquanova Ag Solubilisat med curcumin, boswellia og xanthohumol
RS64651B1 (sr) 2018-07-11 2023-10-31 Aquanova Ag Solubilizat ksantohumola
EP3820527B1 (de) * 2018-07-11 2023-08-23 Aquanova AG Xanthohumol-solubilisat
JP7348187B2 (ja) * 2018-08-10 2023-09-20 サントリーホールディングス株式会社 腸内環境改善用組成物及び腸内細菌叢改善方法
CN112584709A (zh) * 2018-08-10 2021-03-30 三得利控股株式会社 微生物增殖抑制剂、微生物污染防止方法及饮料
CN112566516A (zh) * 2018-08-10 2021-03-26 三得利控股株式会社 血糖值上升抑制用组合物及血糖值上升抑制方法
EP3834627A4 (en) * 2018-08-10 2022-05-04 Suntory Holdings Limited COMPOSITION FOR PROMOTING URIC ACID EXCRETION, COMPOSITION FOR INHIBITING URAT1 AND COMPOSITION FOR LOWERING URIC ACID LEVELS IN THE BLOOD
EP4291307A4 (en) * 2021-02-09 2025-01-22 Oregon State University Xanthohumol derivatives and methods for making and using
US20250009709A1 (en) * 2021-07-09 2025-01-09 INNOX Corp. Prenylated chalcone and flavonoid compositions for use in treating cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679393B1 (en) 1994-04-21 1998-01-14 Hoechst Japan Limited Pharmaceutical composition for treating osteoporosis containing xanthohumol
WO2001003681A2 (en) 1999-07-08 2001-01-18 Prendergast Patrick T Use of flavones, coumarins and related compounds to treat infections
DE10308864A1 (de) 2003-02-28 2004-09-16 Paulaner Brauerei Gmbh & Co. Kg Neues Brauverfahren, damit gebrautes Bier und dessen Verwendung
EP1543834A1 (en) 2003-12-16 2005-06-22 Biodynamics Production of hop extracts having oestrogenic and antiproliferative bioactivity
US20060276372A1 (en) 2005-03-09 2006-12-07 Lockwood Samuel F Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
WO2007016578A2 (en) * 2005-07-29 2007-02-08 Bioactives, Inc. Prenylflavonoid formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0938304T3 (da) * 1996-08-30 2005-03-14 Nps Pharma Inc Isovaleramid til behandlingen af kramper, epilepsi, hovedpine og spasticitet
JP3293601B2 (ja) * 1999-09-03 2002-06-17 松下電器産業株式会社 管球およびその製造方法
CN100457124C (zh) * 2000-04-10 2009-02-04 宝生物工程株式会社 治疗剂
US20040156950A1 (en) * 2001-04-05 2004-08-12 Green Martin Richard Use of hop components in foods
US20040219238A1 (en) * 2001-07-13 2004-11-04 Eiji Nishiyama Remedies
JP2006306800A (ja) * 2005-04-28 2006-11-09 Kirin Brewery Co Ltd ファルネソイドｘ受容体活性化剤
MX2008001903A (es) * 2005-08-09 2008-04-16 Metaproteomics Llc Modulacion de proteina cinasa por medio de lupulos y productos de acacia.
JP5246834B2 (ja) * 2005-12-27 2013-07-24 独立行政法人産業技術総合研究所 アディポネクチン産生強化剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679393B1 (en) 1994-04-21 1998-01-14 Hoechst Japan Limited Pharmaceutical composition for treating osteoporosis containing xanthohumol
WO2001003681A2 (en) 1999-07-08 2001-01-18 Prendergast Patrick T Use of flavones, coumarins and related compounds to treat infections
DE10308864A1 (de) 2003-02-28 2004-09-16 Paulaner Brauerei Gmbh & Co. Kg Neues Brauverfahren, damit gebrautes Bier und dessen Verwendung
EP1543834A1 (en) 2003-12-16 2005-06-22 Biodynamics Production of hop extracts having oestrogenic and antiproliferative bioactivity
US20060276372A1 (en) 2005-03-09 2006-12-07 Lockwood Samuel F Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
WO2007016578A2 (en) * 2005-07-29 2007-02-08 Bioactives, Inc. Prenylflavonoid formulations

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ALBINI ADRIANA ET AL.: "Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappa B and Akt as targets", FASEB JOURNAL, vol. 19, no. 14, December 2005 (2005-12-01), XP002473940
ALBINI ADRIANA ET AL: "Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappa B and Akt as targets", FASEB JOURNAL, vol. 19, no. 14, December 2005 (2005-12-01), XP002473940, ISSN: 0892-6638 *
BUCKWOLD V E ET AL.: "ANTIVIRAL RESEARCH", vol. 61, January 2004, ELSEVIER SCIENCE, article "Antiviral activity ofhop constituents against a series of DNA and RNA viruses", pages: 57 - 62
BUCKWOLD V E ET AL: "Antiviral activity of hop constituents against a series of DNA and RNA viruses", ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV., AMSTERDAM, NL, vol. 61, no. 1, January 2004 (2004-01-01), pages 57 - 62, XP002398448, ISSN: 0166-3542 *
DIETZ BIRGIT M ET AL.: "Xanthohumol isolated from Humulus lupulus inhibits menadione-induced DNA damage through induction of quinone reductase", CHEMICAL RESEARCH IN TOXICOLOGY, vol. 18, no. 8, August 2005 (2005-08-01), pages 1296 - 1305, XP002473941, DOI: doi:10.1021/tx050058x
DIETZ BIRGIT M ET AL: "Xanthohumol isolated from Humulus lupulus inhibits menadione-induced DNA damage through induction of quinone reductase", CHEMICAL RESEARCH IN TOXICOLOGY, vol. 18, no. 8, August 2005 (2005-08-01), pages 1296 - 1305, XP002473941, ISSN: 0893-228X *
GERHAUSER CLARISSA ET AL.: "Cancer chemopreventive activity of Xanthohumol, a natural product derived from hop", MOLECULAR CANCER THE-RAPEUTICS, vol. L, no. 11, September 2002 (2002-09-01), pages 959 - 969
GERHAUSER CLARISSA ET AL: "Cancer chemopreventive activity of Xanthohumol, a natural product derived from hop", MOLECULAR CANCER THERAPEUTICS, vol. 1, no. 11, September 2002 (2002-09-01), pages 959 - 969, XP002473942, ISSN: 1535-7163 *
LEE TZONG-HSIEN ET AL.: "Enhanced nuclear factor-kappa B-associated Wnt-1 expression in hepatitis B- and C-related hepatocarcinogenesis: identification by functional proteomics", JOURNAL OF BIOMEDICAL SCIENCE, vol. 13, no. 1, January 2006 (2006-01-01), pages 27 - 39, XP002473939, DOI: doi:10.1007/s11373-005-9030-1
LEE TZONG-HSIEN ET AL: "Enhanced nuclear factor-kappa B-associated Wnt-1 expression in hepatitis B- and C-related hepatocarcinogenesis: identification by functional proteomics", JOURNAL OF BIOMEDICAL SCIENCE, vol. 13, no. 1, January 2006 (2006-01-01), pages 27 - 39, XP002473939, ISSN: 1021-7770 *
NIKOLIC D ET AL.: "JOURNAL OF MASS SPECTROMTETRY", vol. 40, 15 February 2005, WILEY, article "Metabolism of xanthohumol and isoxanthohumol, prenylated flavonoids from hops (Humulus lupulus L.), by human liver microsomes", pages: 289 - 299
NIKOLIC D ET AL: "Metabolism of xanthohumol and isoxanthohumol, prenylated flavonoids from hops (Humulus lupulus L.), by human liver microsomes", JOURNAL OF MASS SPECTROMETRY, WILEY, CHICHESTER, GB, vol. 40, no. 3, 15 February 2005 (2005-02-15), pages 289 - 299, XP002393640, ISSN: 1076-5174 *
XINGJUN LIU ET AL.: "PHARMACEUTICAL RESEARCH", vol. 23, 1 January 2006, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, article "Smad3 Specific inhibitor, Naringenin, Decreases the Expression of Extracellular Matrix Induced by TGF-[ß] in Cultured Rat Hepatic Stellate Cells", pages: 82 - 89
XINGJUN LIU ET AL: "Smad3 Specific Inhibitor, Naringenin, Decreases the Expression of Extracellular Matrix Induced by TGF-[beta]1 in Cultured Rat Hepatic Stellate Cells", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 23, no. 1, 1 January 2006 (2006-01-01), pages 82 - 89, XP019370960, ISSN: 1573-904X *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064350A1 (en) * 2009-11-26 2011-06-03 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
EP2641596A1 (en) * 2009-11-26 2013-09-25 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US8772342B2 (en) 2009-11-26 2014-07-08 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US8895619B2 (en) 2009-11-26 2014-11-25 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
EA020849B1 (ru) * 2009-11-26 2015-02-27 Женфит Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени
US9221751B2 (en) 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US9585853B2 (en) 2009-11-26 2017-03-07 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US9782373B2 (en) 2009-11-26 2017-10-10 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US10022343B2 (en) 2009-11-26 2018-07-17 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US10350181B2 (en) 2009-11-26 2019-07-16 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
WO2017001020A1 (de) 2015-07-02 2017-01-05 Flaxan Gmbh & Co. Kg Substanz auf hopfenbasis sowie verwendung der substanz

Also Published As

Publication number Publication date
CA2672155C (en) 2013-10-01
JP2010513360A (ja) 2010-04-30
EP2120906B1 (de) 2015-04-22
DE102006062264A1 (de) 2008-06-26
RU2454996C2 (ru) 2012-07-10
JP5513126B2 (ja) 2014-06-04
US20100029757A1 (en) 2010-02-04
RU2009128213A (ru) 2011-01-27
CA2672155A1 (en) 2008-07-03
EP2120906A1 (de) 2009-11-25

Similar Documents

Publication Publication Date Title
WO2008077618A1 (de) Verwendung von xanthohumol bzw. isoxanthohumol als wirkstoff zur vorbeugung und/oder bekämpfung von lebererkrankungen
DE68905096T2 (de) Niacin und guar-mehl enthaltende zusammensetzung.
AT506095A1 (de) Verwendung von proteasen
EP2057994A1 (de) Feigenkakteen-Extraktzubereitung
DE69128760T2 (de) Antidiarrhoeika
DE2718260C2 (de) Verfahren zur Herstellung einer therapeutischen Zusammensetzung
DE69424679T2 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
EP1212072B1 (de) Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl
DE202007008818U1 (de) Zusammensetzung zur Behandlung von Infekten
EP1886690A2 (de) Pharmazeutische Zusammensetzung zur Anwendung bei Nahrungsmittelunverträglichkeiten
EP1871340B1 (de) Reizlinderndes hustenmittel enthaltend extrakte aus isländischem moos und malve sowie zinkverbindungen
DE60102142T2 (de) Kosmetische verwendung von hopfen und ornithin
DE69018022T2 (de) Magnesiumcitrat als Diätzusatzmittel.
DE102012000976A1 (de) Zusammensetzung für die topische Behandlung
EP2386309A1 (de) Bulbine frutescens Gel
DE202009008263U1 (de) Zusammensetzung zur Behandlung entzündlicher Erkrankungen
DE202011004425U1 (de) Zusammensetzung zur Anwendung bei Verdauungsbeschwerden
WO2002087600A1 (de) Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch hepatitis b-viren
EP4366727B1 (de) Neue therapiekonzepte für die behandlung von otitis
EP2355815A1 (de) Verwendung von leukotrien-inhibitoren zur behandlung von lungenerkrankungen bei frühgeborenen kindern
DE2030932C3 (de) Arzneimittel zur oralen Behandlung von Oxalatsteinen
DE102004008375B4 (de) Verwendung von physiologisch verträglichen Ascorbatverbindungen in Kombination mit einem Sympathomimetikum als lokales Therapeutikum für Schleimhäute der Atemwege
DE102017117836A1 (de) Cineolhaltige Zusammensetzung für die Behandlung von nasalen Erkrankungen
DE102023117188A1 (de) Darreichungsform auf Basis von Pflanzenextrakten
EP3445341A1 (de) Verwendung von homoeriodictyol (hed) zum reduzieren der magensäuresekretions-stimulierenden wirkung von n-acetyl-4-aminophenol (paracetamol)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07857069

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2672155

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009541912

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007857069

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009128213

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12520756

Country of ref document: US